Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway.
dc.contributor.author | de Figueiredo-Pontes, Lorena L | |
dc.contributor.author | Assis, Patricia A | |
dc.contributor.author | Santana-Lemos, Bárbara AA | |
dc.contributor.author | Jácomo, Rafael H | |
dc.contributor.author | Lima, Ana Sílvia G | |
dc.contributor.author | Garcia, Aglair B | |
dc.contributor.author | Thomé, Carolina H | |
dc.contributor.author | Araújo, Amélia G | |
dc.contributor.author | Panepucci, Rodrigo A | |
dc.contributor.author | Zago, Marco A | |
dc.contributor.author | Nagler, Arnon | |
dc.contributor.author | Falcão, Roberto P | |
dc.contributor.author | Rego, Eduardo M | |
dc.contributor.editor | Ryffel, Bernhard | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2023-07-06T15:21:01Z | |
dc.date.available | 2023-07-06T15:21:01Z | |
dc.date.issued | 2011 | |
dc.identifier.issn | 1932-6203 | |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pubmed/22053203 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/177161 | en |
dc.description.abstract | Promyelocytic leukemia-retinoic acid receptor alpha (PML-RARα) expression in acute promyelocytic leukemia (APL) impairs transforming growth factor beta (TGFβ) signaling, leading to cell growth advantage. Halofuginone (HF), a low-molecular-weight alkaloid that modulates TGFβ signaling, was used to treat APL cell lines and non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice subjected to transplantation with leukemic cells from human chorionic gonadotrophin-PML-RARα transgenic mice (TG). Cell cycle analysis using incorporated bromodeoxyuridine and 7-amino-actinomycin D showed that, in NB4 and NB4-R2 APL cell lines, HF inhibited cellular proliferation (P<0.001) and induced apoptosis (P = 0.002) after a 24-hour incubation. Addition of TGFβ revealed that NB4 cells were resistant to its growth-suppressive effects and that HF induced these effects in the presence or absence of the cytokine. Cell growth inhibition was associated with up-regulation of TGFβ target genes involved in cell cycle regulation (TGFB, TGFBRI, SMAD3, p15, and p21) and down-regulation of MYC. Additionally, TGFβ protein levels were decreased in leukemic TG animals and HF in vivo could restore TGFβ values to normal. To test the in vivo anti-leukemic activity of HF, we transplanted NOD/SCID mice with TG leukemic cells and treated them with HF for 21 days. HF induced partial hematological remission in the peripheral blood, bone marrow, and spleen. Together, these results suggest that HF has anti-proliferative and anti-leukemic effects by reversing the TGFβ blockade in APL. Since loss of the TGFβ response in leukemic cells may be an important second oncogenic hit, modulation of TGFβ signaling may be of therapeutic interest. | |
dc.language | eng | |
dc.publisher | Public Library of Science (PLoS) | |
dc.subject | Animals | |
dc.subject | Blood Cell Count | |
dc.subject | Cell Line, Tumor | |
dc.subject | Cell Proliferation | |
dc.subject | Disease Models, Animal | |
dc.subject | Dose-Response Relationship, Drug | |
dc.subject | Gene Expression Regulation, Leukemic | |
dc.subject | Humans | |
dc.subject | Leukemia, Promyelocytic, Acute | |
dc.subject | Mice | |
dc.subject | Mice, SCID | |
dc.subject | Oncogene Proteins, Fusion | |
dc.subject | Piperidines | |
dc.subject | Protein Serine-Threonine Kinases | |
dc.subject | Quinazolinones | |
dc.subject | Receptor, Transforming Growth Factor-beta Type II | |
dc.subject | Receptors, Transforming Growth Factor beta | |
dc.subject | Signal Transduction | |
dc.subject | Smad3 Protein | |
dc.subject | Transforming Growth Factor beta | |
dc.subject | Up-Regulation | |
dc.title | Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway. | |
dc.type | Article | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/177161/2/2011:10_Figueiredo-Pontes, LL and Assis PA, et al. PlosOne.pdf | |
dc.identifier.doi | 10.1371/journal.pone.0026713 | |
dc.identifier.doi | https://dx.doi.org/10.7302/7895 | |
dc.identifier.source | PLoS One | |
dc.description.version | Published version | |
dc.date.updated | 2023-07-06T15:21:00Z | |
dc.identifier.volume | 6 | |
dc.identifier.issue | 10 | |
dc.identifier.startpage | e26713 | |
dc.identifier.name-orcid | de Figueiredo-Pontes, Lorena L | |
dc.identifier.name-orcid | Assis, Patricia A | |
dc.identifier.name-orcid | Santana-Lemos, Bárbara AA | |
dc.identifier.name-orcid | Jácomo, Rafael H | |
dc.identifier.name-orcid | Lima, Ana Sílvia G | |
dc.identifier.name-orcid | Garcia, Aglair B | |
dc.identifier.name-orcid | Thomé, Carolina H | |
dc.identifier.name-orcid | Araújo, Amélia G | |
dc.identifier.name-orcid | Panepucci, Rodrigo A | |
dc.identifier.name-orcid | Zago, Marco A | |
dc.identifier.name-orcid | Nagler, Arnon | |
dc.identifier.name-orcid | Falcão, Roberto P | |
dc.identifier.name-orcid | Rego, Eduardo M | |
dc.working.doi | 10.7302/7895 | en |
dc.owningcollname | Pathology, Department of |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.